CompoundAtlas
Sign in

Testosterone Cypionate

72
evidence score
anabolic
Scheduled Substance
241 studies
Test CypTCDepo-Testosterone+1 more

Testosterone Cypionate is a long-acting ester of testosterone, the primary endogenous male androgen. Approved for hypogonadism (TRT) and delayed puberty. The 8-day half-life allows weekly or twice-weekly injections, maintaining stable serum testosterone levels. The gold standard for TRT; extensively studied in clinical medicine. At supraphysiologic doses used in bodybuilding (200–600mg/week), it produces significant muscle hypertrophy, strength, and erythropoiesis but causes HPG axis suppression, erythrocytosis, and estrogen-related side effects via aromatization. Controlled substance (Schedule III).

Evidence

Moderate evidence

Safety

Unknown safety profile

Clinical Status

Approved

Last Sync

Feb 19, 2026

Last Reviewed

Not reviewed yet

Physician Notes

Start low (100-120mg/week), titrate based on trough levels and symptoms. Split dosing (2x/week) reduces E2 spikes and hematocrit elevation. Monitor hematocrit closely. If >52%, reduce dose or consider therapeutic phlebotomy.

FDA Status:FDA-approved for male hypogonadism.

Monitoring

  • Total T + Free T (trough, q3mo initially)
  • Hematocrit/CBC q3mo
  • PSA baseline + q6mo
  • Estradiol (sensitive) q3mo
  • Lipid panel q6mo
  • Liver function baseline + q12mo

Contraindications

  • Polycythemia (Hct >54%)
  • Untreated severe OSA
  • Uncontrolled CHF
  • Active prostate or breast cancer
  • Desire for near-term fertility (without HCG/enclomiphene)
Velix Health

Want this prescribed by a board-certified physician?

Velix Health physicians review your labs, build evidence-based protocols, and monitor your progress. Every prescription is referenced.

Apply for Membership

Dosing

Typical
200 mg
100 mgRange600 mg
FrequencyIntramuscular injection weekly or E3.5D

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~8 days
Onset1–2 weeks for androgen effects; peak levels at 72 hours post-injection
DurationCycle length 8–16 weeks; suppression recovery 3–6 months without PCT
Routes
intramuscular
subcutaneous

Evidence Score

72
Level B — Moderate
241 studies indexed · 2 meta-analyses
Scoring Factors
Volume(24%)~48/100
Quality(24%)~45/100
Sample Size(12%)~95/100
Consistency(14%)~95/100
Replication(8%)~95/100
Recency(18%)~95/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels
AScore ≥75 with at least 1 meta-analysis and 3+ RCTs
BScore ≥50 with at least 1 RCT or meta-analysis
CScore ≥25 — observational or animal evidence only
DScore <25 — very limited or preclinical data

Plain-English Snapshot

Testosterone Cypionate is currently categorized as a anabolic compound.

Evidence is moderate (72/100): promising signal from 241 indexed studies, but context and population still matter.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Binds androgen receptor as full agonist; activates muscle, bone, erythropoiesis, and CNS AR programs; aromatizes to estradiol via CYP19A1

Practical Context

Strongest current signals

  • Level B: Testosterone Effects on Short-term Physical, Hormonal, and Neurodevelopmental Outcomes (TESTO) in Infants With 47,XXY.
  • Level C: Testosterone Replacement Therapy in Men Aged 50 and Above: A Narrative Review of Evidence-Based Benefits, Safety Considerations, and Clinical Recommendations.
  • Level C: Management of Adverse Effects in Testosterone Replacement Therapy.

Elevated caution signals

1 severe/high side effect flag

Compound Profile